NASDAQ:RXST - US78349D1072 - Common Stock
The current stock price of RXST is 9.04 USD. In the past month the price increased by 15.9%. In the past year, price decreased by -83.97%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ALC | ALCON INC | 26.43 | 39.88B | ||
COO | COOPER COS INC/THE | 16.76 | 13.45B | ||
SOLV | SOLVENTUM CORP | 12.02 | 12.67B | ||
ALGN | ALIGN TECHNOLOGY INC | 15.09 | 10.29B | ||
MMSI | MERIT MEDICAL SYSTEMS INC | 24.74 | 5.36B | ||
BLCO | BAUSCH + LOMB CORP | 34.83 | 5.18B | ||
LNTH | LANTHEUS HOLDINGS INC | 8.59 | 3.73B | ||
ICUI | ICU MEDICAL INC | 16.98 | 3.15B | ||
XRAY | DENTSPLY SIRONA INC | 8.36 | 2.85B | ||
HAE | HAEMONETICS CORP/MASS | 11.73 | 2.63B | ||
UFPT | UFP TECHNOLOGIES INC | 24.35 | 1.62B | ||
STAA | STAAR SURGICAL CO | N/A | 1.35B |
RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. The company is headquartered in Aliso Viejo, California and currently employs 498 full-time employees. The company went IPO on 2021-07-30. The firm's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
RXSIGHT INC
100 Columbia Street, Suite 120
Aliso Viejo CALIFORNIA US
CEO: Ron Kurtz
Employees: 498
Phone: 19495217822
The current stock price of RXST is 9.04 USD. The price decreased by -1.2% in the last trading session.
The exchange symbol of RXSIGHT INC is RXST and it is listed on the Nasdaq exchange.
RXST stock is listed on the Nasdaq exchange.
16 analysts have analysed RXST and the average price target is 9.18 USD. This implies a price increase of 1.55% is expected in the next year compared to the current price of 9.04. Check the RXSIGHT INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
RXSIGHT INC (RXST) has a market capitalization of 369.92M USD. This makes RXST a Small Cap stock.
RXSIGHT INC (RXST) currently has 498 employees.
RXSIGHT INC (RXST) has a support level at 8.49 and a resistance level at 9.23. Check the full technical report for a detailed analysis of RXST support and resistance levels.
The Revenue of RXSIGHT INC (RXST) is expected to decline by -10.36% in the next year. Check the estimates tab for more information on the RXST EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
RXST does not pay a dividend.
RXSIGHT INC (RXST) will report earnings on 2025-11-07, after the market close.
RXSIGHT INC (RXST) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.8).
The outstanding short interest for RXSIGHT INC (RXST) is 16.31% of its float. Check the ownership tab for more information on the RXST short interest.
ChartMill assigns a technical rating of 1 / 10 to RXST. When comparing the yearly performance of all stocks, RXST is a bad performer in the overall market: 98.53% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to RXST. The financial health of RXST is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months RXST reported a non-GAAP Earnings per Share(EPS) of -0.8. The EPS increased by 18.37% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -10.44% | ||
ROE | -11.6% | ||
Debt/Equity | 0 |
16 analysts have analysed RXST and the average price target is 9.18 USD. This implies a price increase of 1.55% is expected in the next year compared to the current price of 9.04.
For the next year, analysts expect an EPS growth of -74.25% and a revenue growth -10.36% for RXST